Search Menu Globe Arrow Right Close

Cancer Quality Measures

Cedars-Sinai Cancer aims to deliver the highest-quality care to all our cancer patients. We constantly strive to follow the latest evidence-based guidelines that will result in the best outcomes for our patients. The patient-satisfaction scores listed below show that a significant percentage of our patients would highly recommend our care providers when asked to rank the providers using a scale from 0 to 5, where 0 is the worst/least likely to recommend care provider and 5 is the best/most likely to recommend care provider. The number below represents the percentage of patients who selected the most positive response choice for their care provider.

Patient Satisfaction (July 1, 2022—May 1, 2023)
Likelihood to Recommend Care Provider

Samuel Oschin Cancer Center

94.6%

Saul and Joyce Brandman Breast Center—A Project of Women’s Guild

91.4%

Radiation Oncology

95.2%

Source: Press Ganey

To demonstrate our commitment to quality care, Cedars-Sinai Cancer at Cedars-Sinai Medical Center is accredited by the Commission on Cancer and participates in monitoring care associated with the quality-of-care guidelines for cancer care endorsed by the Commission on Cancer, the National Quality Forum, the American Society of Clinical Oncology and the National Comprehensive Cancer Network.

These quality-of-care guidelines include:

Breast

  • Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast conservation surgery for breast cancer.
  • First therapeutic breast surgery in a non-neoadjuvant setting is performed within 60 days of diagnosis for patients with American Joint Committee on Cancer (AJCC) clinical stage 1-3 breast cancer.

Colorectal

  • At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.

Gastric

  • At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer.

Lung

  • Systemic chemotherapy is administered within four months to day preoperatively or day of surgery to six months postoperatively, or it is recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) non-small cell lung cancer.

Melanoma

  • Melanoma adjuvant systemic therapy was administered within six months of surgery or recommended for eligible patients with stage 3B-3D resected melanoma.

For diagnostic year 2022, Cedars-Sinai’s performance with evidence-based guidelines for cancer care for select cancers/tumor sites is presented below. (Data provided by the National Cancer Database.)

Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast conservation surgery for breast cancer.
Percentage for diagnostic year 2022

Cedars-Sinai

92.17%

State of California

73.51%

Pacific region

78.46%

Teaching hospitals

82.09%

All Commission on Cancer-approved programs

82.11%

First therapeutic breast surgery in a non-neoadjuvant setting is performed within 60 days of diagnosis for patients with AJCC clinical stage 1-3 breast cancer.
Percentage for diagnostic year 2022

Cedars-Sinai

82.39%

State of California

64.05%

Pacific region

69.01%

Teaching hospitals

68.69%

All Commission on Cancer-approved programs

75.33%

At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.
Percentage for diagnostic year 2022

Cedars-Sinai

100%

State of California

94.73%

Pacific region

95.36%

Teaching hospitals

96.64%

All Commission on Cancer-approved programs

95.08%

At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer.
Percentage for diagnostic year 2022

Cedars-Sinai

100%

State of California

76.3%

Pacific region

78.85%

Teaching hospitals

77.9%

All Commission on Cancer-approved programs

73.59%

Systemic chemotherapy is administered within four months to day preoperatively or day of surgery to six months postoperatively, or it is recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) non-small cell lung cancer.
Percentage for diagnostic year 2022

Cedars-Sinai

90%

State of California

80.02%

Pacific region

86.53%

Teaching hospitals

88.64%

All Commission on Cancer-approved programs

90.01%

Melanoma adjuvant systemic therapy was administered within six months of surgery or recommended for eligible patients with stage 3B-3D resected melanoma.
Percentage for diagnostic year 2022

Cedars-Sinai

100%

State of California

76.25%

Pacific region

80%

Teaching hospitals

81.86%

All Commission on Cancer-approved programs

82.66%

Have Questions or Need Help?

If you have questions or wish to learn more about quality measures at Cedars-Sinai, please send us a message.